At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Identification of the Menstrual Cycle-Associated Factors That Modulate Circulating Lipid Levels in Premenopausal Women
In Brief
A clinical study evaluating Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, and 2 other interventions for Coronary Heart Disease. Completed, enrolled 5 participants across 1 site.
Detailed Summary
Women who have regular menstrual cycles have a lower risk of heart disease than men of the same age or women who no longer have menstrual cycles. The purpose of this study is to help determine why the menstrual cycle causes a lower risk of heart disease. The investigators believe that the hormones (estradiol and progesterone) produced during the menstrual cycle, as well as the normal processes occurring in the follicle and corpus luteum (transformed follicle), change levels of "good" and "bad" cholesterol in the blood-stream. These levels of good and bad cholesterol are an important risk factor for heart disease. Therefore, our goal is to determine what effects each of these factors (estradiol, progesterone, follicle, corpus luteum) have on the levels of good and bad cholesterol in the woman's bloodstream. As many women take birth control pills, which contain synthetic forms of estradiol and progesterone that block ovulation and development of a corpus luteum, the investigators also want to determine what effect one common type of birth control pill has on levels of good and bad cholesterol.
Study Details
Timeline
Interventions
0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
single 22.5 mg subcutaneous depot suspension
0.05 to 0.3 mg transdermal daily for 26 days
50 to 100 mg vaginal suppositories twice daily for 13 days